Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Shionogi clinical trials
The registry lists 157 studies whose lead sponsor is Shionogi or one of 4 companies grouped under it. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 26, 2026.
Keep track of what changes. Save the Shionogi studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Shionogi.
- Shionogi105 studiesSame company
Something wrong?
- 25 studies →
- 10 studies →
- 9 studies →
- 8 studies →
Focus areas
Conditions Shionogi leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 157. Browse all 157 →
- A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe DiseaseRecruitingNCT07743580Phase 3
- A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe DiseaseRecruitingNCT07214571Phase 2
- Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult ParticipantsRecruitingNCT07093580Phase 1
- An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)Not yet recruitingNCT07750990Phase 2
- Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy ControlsNot yet recruitingNCT07857837Phase 1
- Study of Secutrelvir in Participants With COVID-19RecruitingNCT07746544Phase 3
- A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)Not yet recruitingNCT07787650Phase 1
- Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving OpioidsRecruitingNCT05588323Phase 1/2
- Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)RecruitingNCT07123155Phase 2
- S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid TumorsRecruitingNCT05101070Phase 1/2
- A Study of S-892216-PO in Participants With Renal Impairment and Matched ControlsCompletedNCT07217886Phase 1
- Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic StrokeCompletedNCT00200356Phase 4
- Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALSTerminatedNCT05151471Phase 3
- Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)CompletedNCT07247266Phase 1
Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi
- Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 InfectionCompletedNCT05897541Phase 3
- A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal ImpairmentCompletedNCT07104162Phase 1
Sponsor listed in the registry: Qpex Biopharma, Inc. · First submitted after Qpex Biopharma, Inc. became part of Shionogi
- Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection FractionCompletedNCT06017609Phase 2
Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi
- A Study of S-892216 in Participants With COVID-19CompletedNCT06928051Phase 2
- A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X SyndromeCompletedNCT05163808Phase 2/3
Sponsor listed in the registry: Tetra Discovery Partners · First submitted after Tetra Discovery Partners became part of Shionogi
- A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19CompletedNCT05305547Phase 3
- A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic StrokeCompletedNCT05953480Phase 2
- Safety Study of Oral Edaravone Administered in Subjects With ALSCompletedNCT04165824Phase 3
- Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral SclerosisCompletedNCT01492686Phase 3
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00330681Phase 3
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification IIICompletedNCT00415519Phase 3
- Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00424463Phase 3
- Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALSCompletedNCT05568615Phase 3
- Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT04577404Phase 3
- Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALSTerminatedNCT04569084Phase 3
- Dose Finding Study of MCI-186 in Acute Ischemic StrokeTerminatedNCT03346538Phase 2
- Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With GastrostomyCompletedNCT04254913Phase 1
- Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic StrokeCompletedNCT00821821Phase 2
- Study of Oral Edaravone in Healthy Adult MalesCompletedNCT04481750Phase 1
- PK Study in Subjects With Severe Hepatic ImpairmentCompletedNCT03664544Phase 1
- Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)CompletedNCT04481789Phase 1
- Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric TubeCompletedNCT04776135Phase 1
- Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral SclerosisCompletedNCT04176224Phase 1
- Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult SubjectsCompletedNCT04493281Phase 1
- Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic ImpairmentCompletedNCT03289234Phase 1
- Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal ImpairmentCompletedNCT03289208Phase 1
- Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)CompletedNCT05342597Phase 1
- A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy SubjectsCompletedNCT04029090Phase 1
- A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X SyndromeCompletedNCT05358886Phase 3
Sponsor listed in the registry: Tetra Discovery Partners · First submitted after Tetra Discovery Partners became part of Shionogi
- Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)CompletedNCT04259255
- Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])Active, not recruitingNCT06717438Phase 2
- Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep ApneaActive, not recruitingNCT06776432Phase 2
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and InfantsCompletedNCT06086626Phase 2
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric ParticipantsCompletedNCT04335539Phase 2
- Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy ControlsCompletedNCT07018492Phase 1
- Study of BPN14770 in Participants With Severe Renal Impairment and Healthy ControlsCompletedNCT07012005Phase 1